- Home
- ALLT vs MYGN Comparison
ALLT vs MYGN Comparison
Compare ALLT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLT | MYGN |
|---|---|---|
| Founded | 1996 | 1991 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 547.2M |
| IPO Year | 2006 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ALLT | MYGN |
|---|---|---|
| Price | $10.21 | $4.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $13.25 | $10.67 |
| AVG Volume (30 Days) | 346.0K | ★ 949.4K |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $98,512,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $12.28 | $0.05 |
| Revenue Next Year | $12.95 | $5.54 |
| P/E Ratio | $484.06 | ★ N/A |
| Revenue Growth | ★ 7.51 | 0.21 |
| 52 Week Low | $4.37 | $3.76 |
| 52 Week High | $11.92 | $15.47 |
Technical Indicators
Market Signals| Indicator | ALLT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 23.49 |
| Support Level | $9.11 | $5.03 |
| Resistance Level | $10.79 | $5.29 |
| Average True Range (ATR) | 0.51 | 0.26 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 59.35 | 0.84 |
Price Performance
Historical ComparisonAbout ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.